electroCore, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
BASKING RIDGE, N.J., June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 780,000 shares of common stock from electroCore at the initial public offering price of $15.00 per share, less underwriting discounts and commissions. Including exercise of the option, electroCore issued a total of 5,980,000 shares, resulting in aggregate proceeds of approximately $83,421,000, net of underwriting discounts and commissions. All shares of common stock in the offering were sold by electroCore.
electroCore’s common stock trades on the Nasdaq Global Select Market under the symbol ECOR.
Evercore ISI, Cantor Fitzgerald & Co. and JMP Securities acted as joint book-running managers for the offering. BTIG, LLC acted as lead manager.
A registration statement related to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective by the SEC the on June 21, 2018. Copies of the registration statement may be accessed through the SEC’s website at www.sec.gov.
The offering was made only by means of a prospectus forming part of the registration statement. Copies of the final prospectus related to the offering may be obtained from: Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by phone at (888) 474-0200, or by email at firstname.lastname@example.org; Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 5th Floor, New York, NY 10022, or by phone at (212) 829-7122, or by email at email@example.com; or JMP Securities LLC, 600 Montgomery Street, 11th Floor, San Francisco, California 94111, or by phone at (415) 835-8985, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the acute treatment of migraine and episodic cluster headache.
Greg Chodaczek or Lynn Lewis
© 2018 GlobeNewswire, Inc. All Rights Reserved.